{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T07:36:03Z","timestamp":1768808163912,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,18]]},"DOI":"10.7759\/cureus.101793","type":"journal-article","created":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T17:56:02Z","timestamp":1768758962000},"source":"Crossref","is-referenced-by-count":0,"title":["Hepatic-Predominant Immunoglobulin G Lambda Light Chain Amyloidosis Associated With Multiple Myeloma: A Report of an Exceptionally Rare Case"],"prefix":"10.7759","author":[{"given":"Guilherme","family":"Jesus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00eas","family":"Soares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Sofia","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Baptista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Gon\u00e7alves Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic amyloidosis recognition, prognosis, and therapy: a systematic review","volume":"324","author":"Gertz MA","year":"2020","unstructured":"Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy: a systematic review. JAMA. 2020, 324:79-89. 10.1001\/jama.2020.5493","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini G","year":"2018","unstructured":"Merlini G, Dispenzieri A, Sanchorawala V, Sch\u00f6nland SO, Palladini G, Hawkins PN, Gertz MA. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018, 4:38. 10.1038\/s41572-018-0034-3","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar SV","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, et al.. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014, 15:538-48. 10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.8499","article-title":"Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis","volume":"31","author":"Kourelis TV","year":"2013","unstructured":"Kourelis TV, Kumar SK, Gertz MA, et al.. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol. 2013, 31:4319-24. 10.1200\/JCO.2013.50.8499","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-629790","article-title":"What is new in diagnosis and management of light chain amyloidosis?","volume":"128","author":"Palladini G","year":"2016","unstructured":"Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis?. Blood. 2016, 128:159-68. 10.1182\/blood-2016-01-629790","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000091183.93122.c7","article-title":"Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients","volume":"82","author":"Park MA","year":"2003","unstructured":"Park MA, Mueller PS, Kyle RA, Larson DR, Plevak MF, Gertz MA. Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Medicine (Baltimore). 2003, 82:291-8. 10.1097\/01.md.0000091183.93122.c7","journal-title":"Medicine (Baltimore)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510250122","article-title":"Hepatic amyloidosis: clinical appraisal in 77 patients","volume":"25","author":"Gertz MA","year":"1997","unstructured":"Gertz MA, Kyle RA. Hepatic amyloidosis: clinical appraisal in 77 patients. Hepatology. 1997, 25:118-21. 10.1002\/hep.510250122","journal-title":"Hepatology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle RA","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE, et al.. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003, 78:21-33. 10.4065\/78.1.21","journal-title":"Mayo Clin Proc"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2022.2069281","article-title":"The clinical features and outcomes of systemic light chain amyloidosis with hepatic involvement","volume":"54","author":"Zhao L","year":"2022","unstructured":"Zhao L, Ren G, Guo J, Chen W, Xu W, Huang X. The clinical features and outcomes of systemic light chain amyloidosis with hepatic involvement. Ann Med. 2022, 54:1226-32. 10.1080\/07853890.2022.2069281","journal-title":"Ann Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"98","author":"Phelan D","year":"2012","unstructured":"Phelan D, Collier P, Thavendiranathan P, et al.. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012, 98:1442-8. 10.1136\/heartjnl-2012-302353","journal-title":"Heart"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2019.10.011","article-title":"Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis","volume":"13","author":"Boldrini M","year":"2020","unstructured":"Boldrini M, Cappelli F, Chacko L, et al.. Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2020, 13:909-20. 10.1016\/j.jcmg.2019.10.011","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar S","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, et al.. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016, 17:328-46. 10.1016\/S1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar S","year":"2012","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, et al.. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012, 30:989-95. 10.1200\/JCO.2011.38.5724","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp PR","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, et al.. International staging system for multiple myeloma. J Clin Oncol. 2005, 23:3412-20. 10.1200\/JCO.2005.04.242","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini G","year":"2012","unstructured":"Palladini G, Dispenzieri A, Gertz MA, et al.. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012, 30:4541-9. 10.1200\/JCO.2011.37.7614","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-453001","article-title":"Systemic light chain amyloidosis: an update for treating physicians","volume":"121","author":"Merlini G","year":"2013","unstructured":"Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood. 2013, 121:5124-30. 10.1182\/blood-2013-01-453001","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari A","year":"2017","unstructured":"Chari A, Suvannasankha A, Fay JW, et al.. Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma. Blood. 2017, 130:974-81. 10.1182\/blood-2017-05-785246","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis E","year":"2021","unstructured":"Kastritis E, Palladini G, Minnema MC, et al.. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021, 385:46-58. 10.1056\/NEJMoa2028631","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.227","article-title":"Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients","volume":"28","author":"Palladini G","year":"2014","unstructured":"Palladini G, Milani P, Foli A, et al.. Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients. Leukemia. 2014, 28:2311-16. 10.1038\/leu.2014.227","journal-title":"Leukemia"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri A","year":"2004","unstructured":"Dispenzieri A, Gertz MA, Kyle RA, et al.. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004, 22:3751-7. 10.1200\/JCO.2004.03.029","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/433253-hepatic-predominant-immunoglobulin-g-lambda-light-chain-amyloidosis-associated-with-multiple-myeloma-a-report-of-an-exceptionally-rare-case","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T17:56:02Z","timestamp":1768758962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/433253-hepatic-predominant-immunoglobulin-g-lambda-light-chain-amyloidosis-associated-with-multiple-myeloma-a-report-of-an-exceptionally-rare-case"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,18]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.101793","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,18]]}}}